以岭药业：全资子公司苯胺洛芬注射液获药品注册证书

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Yiling Wanzhou International Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization of Anilofin Injection (brand name: Wanshuan), which is a patented chemical drug for postoperative analgesia [1] Group 1: Product Approval - The injection is a new chemical drug indicated for postoperative pain relief [1] - The approval provides a new option for clinical postoperative analgesia, enriching the company's chemical drug pipeline [1] Group 2: Market Context - In 2024, the number of surgical procedures in China is projected to reach 104 million, representing an 8% year-on-year increase [1] - The drug's sales and production may be influenced by market policies and other factors [1]